FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.